170 related articles for article (PubMed ID: 11957133)
1. In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species.
Miyashita N; Fukano H; Yoshida K; Niki Y; Matsushima T
J Infect Chemother; 2002 Mar; 8(1):115-7. PubMed ID: 11957133
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
Miyashita N; Niki Y; Kishimoto T; Nakajima M; Matsushima T
Antimicrob Agents Chemother; 1997 Jun; 41(6):1331-4. PubMed ID: 9174194
[TBL] [Abstract][Full Text] [Related]
3. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.
Donati M; Rodrìguez Fermepin M; Olmo A; D'Apote L; Cevenini R
J Antimicrob Chemother; 1999 Jun; 43(6):825-7. PubMed ID: 10404322
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
[TBL] [Abstract][Full Text] [Related]
5. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
Dorai-John T; Thomson CJ; Amyes SG
J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
[TBL] [Abstract][Full Text] [Related]
6. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Hammerschlag MR; Roblin PM
Int J Antimicrob Agents; 2000 Jul; 15(2):149-52. PubMed ID: 10854812
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae.
Reinert RR; Schlaeger JJ; Lütticken R
J Antimicrob Chemother; 1998 Dec; 42(6):803-6. PubMed ID: 10052905
[TBL] [Abstract][Full Text] [Related]
8. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.
Hamamoto K; Shimizu T; Fujimoto N; Zhang Y; Arai S
Antimicrob Agents Chemother; 2001 Jun; 45(6):1908-10. PubMed ID: 11353651
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
Lister PD; Sanders CC
J Antimicrob Chemother; 2001 Jun; 47(6):811-8. PubMed ID: 11389113
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of sitafloxacin against Chlamydia spp.
Miyashita N; Niki Y; Matsushima T
Antimicrob Agents Chemother; 2001 Nov; 45(11):3270-2. PubMed ID: 11600398
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
Roblin PM; Hammerschlag MR
Antimicrob Agents Chemother; 1998 Apr; 42(4):951-2. PubMed ID: 9559818
[TBL] [Abstract][Full Text] [Related]
13. Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration.
Patmore L; Fraser S; Mair D; Templeton A
Eur J Pharmacol; 2000 Oct; 406(3):449-52. PubMed ID: 11040352
[TBL] [Abstract][Full Text] [Related]
14. Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates.
Speciale A; Musumeci R; Blandino G; Milazzo I; Caccamo F; Nicoletti G
Int J Antimicrob Agents; 2002 Feb; 19(2):111-8. PubMed ID: 11850163
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Patel T; Pearl J; Williams J; Haverstock D; Church D
Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
[TBL] [Abstract][Full Text] [Related]
16. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
Balfour JA; Lamb HM
Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates.
Wilcox MH; Fawley W; Freeman J; Brayson J
J Antimicrob Chemother; 2000 Oct; 46(4):551-6. PubMed ID: 11020251
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
Yamada M; Hatou S; Yoshida J
Eye Contact Lens; 2008 Mar; 34(2):109-12. PubMed ID: 18327047
[TBL] [Abstract][Full Text] [Related]
19. Fluoroquinolone resistance during 2000-2005: an observational study.
Ryan RJ; Lindsell C; Sheehan P
BMC Infect Dis; 2008 May; 8():71. PubMed ID: 18501015
[TBL] [Abstract][Full Text] [Related]
20. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
Esposito S; Noviello S; Ianniello F
J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
